Pharmacokinetics, Safety, Tolerability and Efficacy of a Subcutaneous Long-Acting Injection of Cariprazine (Cariprazine Depot) in Subjects Eligible for Treatment With Oral Cariprazine

Not Applicable

Recruiting

• Conditions: Major Depressive Disorder (MDD); Bipolar 1 Disorder; Schizophrenia
• Interventions: Drug: Cariprazine Depot; Drug: Cariprazine Depot MTD; Drug: Oral Cariprazine 3 mg/day

• Registration Number: NCT07185815
• Lead Sponsor: Mapi Pharma Ltd.

Brief Summary

The purpose of this study is to assess the PK, Safety, Tolerability (all cohorts) and Efficacy (cohort 3), of once-a-month long-acting SC injection of dose escalating Cariprazine Depot in subjects eligible for treatment with oral Cariprazine.

Detailed Description

Not available

Study Timeline

• Study Start: 2025-08-01
• Study First Submitted: 2025-08-28
• Status Verified: 2025-09
• Study First Submitted QC: 2025-09-15
• Last Update Submitted: 2025-09-15
• Study First Posted: 2025-09-22
• Last Update Posted: 2025-09-22
• Primary Completion: 2026-12-31
• Study Completion: 2027-06-03

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 24

Inclusion Criteria

• Subjects who meet DSM-5-TR diagnostic criteria for schizophrenia, bipolar I disorder or major depressive disorder (this inclusion criterion relates to cohorts 1 and 2 only).
• Clinically stable subjects (with no evidence of deterioration and on a stable dose of oral antipsychotic or antidepressant medication(s) other than Cariprazine for at least 4 weeks, prior to screening), receiving antipsychotic/s or antidepressant/s other than oral Cariprazine and eligible for treatment with Cariprazine 3 mg/day, with CGI-S score of 0-4.
• Men and women aged 18-64 years (inclusive).
• Body mass index (BMI) 18.5-35.
• Able to sign an informed consent form.
• Adult subjects with a current diagnosis of schizophrenia, who meet DSM-5-TR diagnostic criteria for schizophrenia, naïve to or treated with antipsychotics (this inclusion criterion relates to cohort 3 only).

Key

Exclusion Criteria

• Subjects with schizophrenia with PANSS item scores of > 4 on any of the following: P4 Excitement/Hyperactivity; P6 Suspiciousness/persecution; P7 Hostility; G8 Uncooperativeness; G14 Poor impulse control.
• Subjects with schizoaffective disorder, delirium, dementia, amnestic, or other cognitive disorders or severe personality disorders.
• Use of an investigational drug, and/or participation in clinical studies with an investigational product within 3 months prior to screening.
• History or current cardiovascular or cerebrovascular disease.
• History of seizures or conditions that lower the seizure threshold.
• Use of concomitant administration of strong or moderate CYP3A4 inhibitors.
• Use of concomitant medication of strong or moderate CYP3A4 inducers is contraindicated.
• Subjects with Suicidal Thoughts and Behaviors or has a history of suicidal ideation in the past year, or made a suicide attempt in the past 5 years.
• Subjects with a history of orthostatic hypotension and/or syncope.
• Subjects clinically stable on any dose of oral Cariprazine or add-on treatment (cohorts 1-2 only).
• Subjects with CGI-S score of 5-7.
• Subjects previously treated with partial D2 agonists, aripiprazole and brexipiprazole, and suffered from clinically relevant akathisia.
• For cohort 3 only: Subjects treated with oral Clozapine.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SEQUENTIAL

Arm && Interventions

Group	Intervention	Description
Cohort 1	Cariprazine Depot	-
Cohort 3	Cariprazine Depot MTD	-
Cohort 2	Cariprazine Depot	-
Cohort 3	Oral Cariprazine 3 mg/day	-

Primary Outcome Measures

Name	Time	Method
Safety, rate of adverse events (AEs)	Through study completion, up to 22 weeks for each subject in the first 2 cohorts and up to 24 weeks for each subject in the 3rd cohort
Plasma concentration of cariprazine and its active metabolites (DCAR, DDCAR)	Through study completion, up to 22 weeks for each subject in the first 2 cohorts and up to 24 weeks for each subject in the 3rd cohort

Secondary Outcome Measures

Name	Time	Method
Tolerability - Incidence and severity of injection site reactions	Through study completion, up to 22 weeks for each subject in the first 2 cohorts and up to 24 weeks for each subject in the 3rd cohort
Efficacy - Cohort 3: Positive and Negative Symptom Score (PANSS)	Through study completion, up to 24 weeks for each subject in the 3rd cohort
Efficacy - Cohort 3: Clinical Global Impression Scale (CGI)	Through study completion, up to 24 weeks for each subject in the 3rd cohort

Trial Locations

Locations (1)

Tel Aviv, Israel; 🇮🇱 Tel Aviv, Israel